Equities analysts forecast that Alpine Immune Sciences Inc (NASDAQ:ALPN) will announce $340,000.00 in sales for the current quarter, Zacks reports. Three analysts have provided estimates for Alpine Immune Sciences’ earnings, with the lowest sales estimate coming in at $300,000.00 and the highest estimate coming in at $400,000.00. Alpine Immune Sciences posted sales of $130,000.00 during the same quarter last year, which would indicate a positive year over year growth rate of 161.5%. The company is scheduled to report its next quarterly earnings results on Monday, November 12th.
According to Zacks, analysts expect that Alpine Immune Sciences will report full-year sales of $1.24 million for the current financial year, with estimates ranging from $710,000.00 to $1.61 million. For the next fiscal year, analysts expect that the company will report sales of $1.42 million, with estimates ranging from $1.00 million to $2.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Alpine Immune Sciences.
Alpine Immune Sciences (NASDAQ:ALPN) last issued its quarterly earnings results on Thursday, August 9th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.44) by ($0.13). The firm had revenue of $0.39 million during the quarter, compared to analyst estimates of $0.30 million. Alpine Immune Sciences had a negative return on equity of 26.00% and a negative net margin of 1,602.19%.
ALPN has been the topic of a number of recent analyst reports. Piper Jaffray Companies initiated coverage on shares of Alpine Immune Sciences in a research report on Thursday, September 27th. They issued an “overweight” rating and a $12.00 price target on the stock. Raymond James initiated coverage on shares of Alpine Immune Sciences in a research report on Monday, August 13th. They issued a “buy” rating and a $13.00 price target on the stock. ValuEngine upgraded shares of Alpine Immune Sciences from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 26th. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research report on Wednesday, July 25th. Finally, Oppenheimer initiated coverage on shares of Alpine Immune Sciences in a research report on Friday, June 29th. They issued an “outperform” rating and a $13.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating and five have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $12.67.
Shares of NASDAQ ALPN opened at $5.00 on Friday. The company has a market capitalization of $87.65 million, a PE ratio of -4.25 and a beta of 0.54. Alpine Immune Sciences has a 52-week low of $4.89 and a 52-week high of $12.24. The company has a debt-to-equity ratio of 0.05, a quick ratio of 20.99 and a current ratio of 20.99.
Several large investors have recently added to or reduced their stakes in ALPN. DRW Securities LLC increased its stake in shares of Alpine Immune Sciences by 138.7% in the 2nd quarter. DRW Securities LLC now owns 24,343 shares of the biotechnology company’s stock valued at $184,000 after acquiring an additional 14,143 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Alpine Immune Sciences by 122.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock valued at $248,000 after acquiring an additional 18,052 shares in the last quarter. Finally, Renaissance Technologies LLC increased its stake in shares of Alpine Immune Sciences by 20.9% in the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock valued at $927,000 after acquiring an additional 21,124 shares in the last quarter. Institutional investors own 56.87% of the company’s stock.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Featured Story: Understanding Price to Earnings Ratio (PE)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.